ID

34303

Descripción

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD); ODM derived from: https://clinicaltrials.gov/show/NCT01295710

Link

https://clinicaltrials.gov/show/NCT01295710

Palabras clave

  1. 16/1/19 16/1/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

16 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility GVHD NCT01295710

Eligibility GVHD NCT01295710

  1. StudyEvent: Eligibility
    1. Eligibility GVHD NCT01295710
Criteria
Descripción

Criteria

patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome)
Descripción

ID.1

Tipo de datos

boolean

patients with an unrelated hla-a,-b, -c and -drbi matched donor
Descripción

ID.2

Tipo de datos

boolean

patients with a karnofsky performance score ≥ 70%
Descripción

ID.3

Tipo de datos

boolean

key exclusion criteria:
Descripción

ID.4

Tipo de datos

boolean

clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and cns)
Descripción

ID.5

Tipo de datos

boolean

bacterial, viral, or fungal infections
Descripción

ID.6

Tipo de datos

boolean

known positive for hepatitis b surfaces antigen, or hepatitis c antibody, or who have been tested positive for hiv
Descripción

ID.7

Tipo de datos

boolean

patients with any concurrent malignancy. cancer treated with curative intent < 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ
Descripción

ID.8

Tipo de datos

boolean

known contraindications to the administration of rabbit immunoglobulin antibodies
Descripción

ID.9

Tipo de datos

boolean

hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products
Descripción

ID.10

Tipo de datos

boolean

Similar models

Eligibility GVHD NCT01295710

  1. StudyEvent: Eligibility
    1. Eligibility GVHD NCT01295710
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
ID.1
Item
patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome)
boolean
ID.2
Item
patients with an unrelated hla-a,-b, -c and -drbi matched donor
boolean
ID.3
Item
patients with a karnofsky performance score ≥ 70%
boolean
ID.4
Item
key exclusion criteria:
boolean
ID.5
Item
clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and cns)
boolean
ID.6
Item
bacterial, viral, or fungal infections
boolean
ID.7
Item
known positive for hepatitis b surfaces antigen, or hepatitis c antibody, or who have been tested positive for hiv
boolean
ID.8
Item
patients with any concurrent malignancy. cancer treated with curative intent < 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ
boolean
ID.9
Item
known contraindications to the administration of rabbit immunoglobulin antibodies
boolean
ID.10
Item
hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial